Cromafiban: Phase II

CORR said that data from a 106-patient Phase II pharmacologic trial showed that cromafiban has properties not seen with other oral GPIIb/IIIa inhibitors (see BioCentury, Aug. 16). The compound had a 21-hour half life, which CORR said is sufficient for once daily dosing, and clinically relevant doses of the compound (that produced 40-70 percent inhibition of platelet aggregation) showed little variability between peak and trough levels of platelet inhibition. Mild bleeding was seen but no major bleeding complications were reported. ...